feedback

Course Director

Toni K. Choueiri, MD
Toni K. Choueiri, MD

Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Faculty

Hans J. Hammers
Hans J. Hammers, MD, PhD

UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Rana R. McKay
Rana R. McKay, MD

UC San Diego Moores Cancer Center
University of California San Diego
La Jolla, California

Accredited by

Medical Learning Institute, Inc.

Activity Description

The treatment armamentarium for advanced renal cell carcinoma (RCC) has undergone rapid expansion with the validation of novel multitargeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. More recently, the emergence of dual checkpoint blockade and immunotherapy-TKI combinations in RCC has increased the number of treatment choices in the frontline setting, allowed for greater flexibility when selecting second-line agents, and sparked additional research into TKI and immune checkpoint inhibitor options in earlier disease settings. In the wake of these advances, understanding how to effectively select and sequence newer regimens through multiple lines of therapy while ensuring safe usage is crucial to maximize beneficial patient outcomes throughout the advanced RCC continuum.

This unique “How I Think, How I Treat” educational on-demand activity, based on an event held adjunct to the 18th International Kidney Cancer Symposium, features personal insights from leading kidney cancer experts on how they are adapting their own practice based on the evidence supporting optimized care in advanced RCC in the context of patient-, disease-, and treatment-specific factors, as well as how the innovations fueling modern approaches to care are improving outcomes for patients with RCC.

Target Audience

This activity has been designed to meet the educational needs of medical and urologic oncologists, nephrologists, surgeons, researchers, and other clinicians involved in the management of patients with RCC.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Assess the latest evidence and clinical implications of novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies in advanced renal cell carcinoma (RCC)
  • Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment
  • Apply validated targeted therapy and immunotherapy options effectively for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities
  • Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC

Providership, Credit, and Support

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported through independent medical educational grants from Bristol-Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.

Physician Continuing Medical Education


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

Chair
Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute
The Jerome and Nancy Kohlberg Endowed Chair
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Toni K. Choueiri, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb/ER Squibb & Sons LLC; Cerulean Pharma Inc.; Corvus Pharmaceuticals; Eisai Inc.; Eli Lilly and Company; EMD Serono, Inc.; Exelixis, Inc.; Foundation Medicine Inc.; Genentech, Inc.; GlaxoSmithKline; Heron Therapeutics, Inc.; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; National Comprehensive Cancer Network (NCCN); Novartis Pharmaceuticals Corporation; Peloton Therapeutics; Pfizer; Pionyr Immunotherapeutics, Inc.; Prometheus Laboratories Inc.; Roche; sanofi-aventis U.S. LLC; Tempest Therapeutics, Inc.; and Up-to-Date.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb/ER Squibb & Sons LLC; Calithera; Cerulean Pharma Inc.; Corvus Pharmaceuticals; Department of Defense (DOD); Eisai Inc.; Eli Lilly and Company; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Foundation Medicine Inc.; Genentech, Inc.; GlaxoSmithKline; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; National Cancer Institute (NCI); National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Peloton Therapeutics; Pfizer; Prometheus Laboratories Inc.; Roche, Roche Products Limited; sanofi-aventis U.S. LLC; Takeda Pharmaceuticals U.S.A., Inc.; and Tracon Pharmaceuticals, Inc.
Honoraria from Alexion Pharmaceuticals, Inc.; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb/ER Squibb & Sons LLC; Cerulean Pharma Inc.; Corvus Pharmaceuticals; Eisai Inc.; Eli Lilly and Company; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Foundation Medicine Inc.; Genentech, Inc.; GlaxoSmithKline; Heron Therapeutics, Inc.; Ipsen Biopharmaceuticals, Inc.; L-path; Merck & Co., Inc.; National Comprehensive Cancer Network (NCCN); Navinata Health, Inc.; Novartis Pharmaceuticals Corporation; Peloton Therapeutics; Pfizer; Prometheus Laboratories Inc.; Roche, Roche Products; sanofi-aventis U.S. LLC; and Up-to-Date.
Stock Shareholder in Pionyr Immunotherapeutics, Inc. and Tempest Therapeutics, Inc.
Other financial interest/relationship Patents, royalties, or other intellectual properties: International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response,” filed January 3, 2018, claiming priority to U.S. Provisional Patent Application No. 62/445,094, filed January 11, 2017. International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy,” filed October 31, 2018, claiming priority to U.S. Provisional Patent Application No. 62/581,175, filed November 3, 2017.

Faculty
Hans J. Hammers, MD, PhD
Associate Professor of Internal Medicine
Division of Hematology and Oncology
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Hans J. Hammers, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Exelixis, Inc.; Merck & Co.; Novartis Pharmaceuticals Corporation; and Pfizer.
Grant/Research Support from Bristol-Myers Squibb and Merck & Co. Grant/Research support goes to institution.
Honorarium from Bristol-Myers Squibb.
Other financial interest/relationship Bristol-Myers Squibb and Merck & Co., Inc. for travel, accommodations and expenses.

Rana R. McKay, MD
Co-Leader, Genitourinary Oncology Disease Team
UC San Diego Moores Cancer Center
Assistant Professor of Medicine
University of California San Diego
La Jolla, California

Rana R. McKay, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Dendreon Pharmaceuticals, Inc.; Exelixis, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.
Grant/Research Support from Bayer (institution) and Pfizer.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:

Natalie I. Vokes, MD

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.